Literature DB >> 15062159

Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy.

Nelson N Stone1, Suzanne Hong, Yeh-Chi Lo, Victor Howard, Richard G Stock.   

Abstract

PURPOSE: To compare the results of intraoperative dosimetry with those of CT-based postimplant dosimetry in patients undergoing prostate seed implantation. METHODS AND MATERIALS: Seventy-seven patients with T1-T3 prostate cancer received an ultrasound-guided permanent seed implant (36 received (125)I, 7 (103)Pd, and 34 a partial (103)Pd implant plus external beam radiation therapy). The implantation was augmented with an intraoperative dosimetric planning system. After the peripheral needles were placed, 5-mm axial images were acquired into the treatment planning system. Soft tissue structures (prostate, urethra, and rectum) were contoured, and exact needle positions were registered. Seeds were placed with an applicator, and their positions were entered into the planning system. The dose distributions for the implant were calculated after interior needle and seed placement. Postimplant dosimetry was performed 1 month later on the basis of CT imaging. Prostate and urethral doses were compared, by using paired t tests, for the real-time dosimetry in the operating room (OR) and the postimplant dosimetry.
RESULTS: The mean preimplant prostate volume was 39.8 cm(3), the postneedle planning volume was 41.5 cm(3) (p<0.001), and the 1-month CT volume was 43.6 cm(3) (p<0.001). The mean difference between the OR dose received by 90% of the prostate (D(90)) and the CT D(90) was 3.4% (95% confidence interval, 2.5-6.6%; p=0.034). The mean dose to 30% of the urethra was 120% of prescription in the OR and 138% on CT. The mean difference was 18% (95% confidence interval, 13-24%; p<0.001).
CONCLUSIONS: Although small differences exist between the OR and CT dosimetry results, these data suggest that this intraoperative implant dosimetric representation system provides a close match to the actual delivered doses. These data support the use of this system to modify the implant during surgery to achieve more consistent dosimetry results.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15062159     DOI: 10.1016/S1538-4721(03)00005-9

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  15 in total

Review 1.  The evolution of brachytherapy for prostate cancer.

Authors:  Nicholas G Zaorsky; Brian J Davis; Paul L Nguyen; Timothy N Showalter; Peter J Hoskin; Yasuo Yoshioka; Gerard C Morton; Eric M Horwitz
Journal:  Nat Rev Urol       Date:  2017-06-30       Impact factor: 14.432

2.  AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137.

Authors:  Ravinder Nath; William S Bice; Wayne M Butler; Zhe Chen; Ali S Meigooni; Vrinda Narayana; Mark J Rivard; Yan Yu
Journal:  Med Phys       Date:  2009-11       Impact factor: 4.071

3.  Clinical research on the treatment effects of radioactive (125)I seeds interstitial brachytherapy on children with primary orbital rhabdomyosarcoma.

Authors:  Xin Ge; Jianmin Ma; Haojie Dai; Ling Ren; Quan Li; Jitong Shi
Journal:  Med Oncol       Date:  2014-08-05       Impact factor: 3.064

4.  On the need to compensate for edema-induced dose reductions in preplanned (131)Cs prostate brachytherapy.

Authors:  Z Jay Chen; Jun Deng; Kenneth Roberts; Ravinder Nath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-05       Impact factor: 7.038

5.  Brachytherapy for prostate cancer: a systematic review.

Authors:  Georgios Koukourakis; Nikolaos Kelekis; Vassilios Armonis; Vassilios Kouloulias
Journal:  Adv Urol       Date:  2009-09-01

6.  Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer.

Authors:  Sarah L Kerns; Richard G Stock; Nelson N Stone; Seth R Blacksburg; Lynda Rath; Ana Vega; Laura Fachal; Antonio Gómez-Caamaño; Dirk De Ruysscher; Guido Lammering; Matthew Parliament; Michael Blackshaw; Michael Sia; Jamie Cesaretti; Mitchell Terk; Rosetta Hixson; Barry S Rosenstein; Harry Ostrer
Journal:  Radiother Oncol       Date:  2013-05-26       Impact factor: 6.280

7.  Preoperative treatment planning with intraoperative optimization can achieve consistent high-quality implants in prostate brachytherapy.

Authors:  Rajat J Kudchadker; Thomas J Pugh; David A Swanson; Teresa L Bruno; Yasemin Bolukbasi; Steven J Frank
Journal:  Med Dosim       Date:  2012-05-03       Impact factor: 1.482

8.  Evaluation of dosimetry and excess seeds in permanent brachytherapy using a modified hybrid method: a single-institution experience.

Authors:  Kana Kobayashi; Koji Okihara; Tsuyoshi Iwata; Norihiro Aibe; Naohiro Kodani; Takuji Tsubokura; Kazumi Kamoi; Tsuneharu Miki; Hideya Yamazaki
Journal:  J Radiat Res       Date:  2013-01-04       Impact factor: 2.724

9.  Benefits of a dual sagittal crystal transducer for ultrasound imaging during I-125 seed implantation for permanent prostate brachytherapy.

Authors:  Emmie Kaljouw; Bradley Pieters; Kees Koedooder; Cees Lucas; Caro Koning
Journal:  J Contemp Brachytherapy       Date:  2012-09-29

10.  Progressive transition from pre-planned to intraoperative optimizing seed implant: post implementation analysis.

Authors:  Hsiang-Chi Kuo; William Bodner; Ravindra Yaparpalvi; Chandan Guha; Bhupendra M Tolia; Keyur J Mehta; Dennis Mah; Shalom Kalnicki
Journal:  J Contemp Brachytherapy       Date:  2012-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.